< Back to latest news & events

Knowledge Hub

UK will no longer seek to participate in unitary patent and UPC

March 2020

The UK Government has confirmed the UK will no longer seek to be part of the proposed unitary patent (UP) or Unified Patent Court (UPC) systems. Given the UPC’s alignment with the CJEU, this is not entirely surprising for the UK in a post-Brexit world.

Although it will be unwelcome news for many, the certainty of this new stance may mean the UP and UPC can again pick up momentum, subject to the ongoing legal challenge in Germany and re-working of the agreements without the UK’s participation.

Should the UP and UPC agreements be ratified as per the current proposals, UK business will still be able to use the Unified Patent Court and unitary patent to protect their inventions within the contracting EU countries. However, in the UK, businesses will only have the option of protecting their inventions using national patents (including patents available from the non-EU European Patent Office) and UK courts.

UK business will still be open to litigation within the Unified Patent Court based on actions they undertake within the contracting EU countries if they infringe existing rights.

EU business will not be able to use the Unified Patent Court and unitary patent to protect their inventions within the UK but will be able to apply for domestic UK rights as they can now, via the UK Intellectual Property Office and the European Patent Office.

This update was prepared by HGF Partner Martyn Fish. If you would like further advice on this or any other matter, please contact Martyn.  Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

The FoodTech Series #1 | Medicament, functional food, nutritive product in the same claim 1: when your own examples no longer support the “improvement”

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article